Can Body Mass Index Affect Height Growth at Menarche among Girls Receiving Treatment for Early Puberty? A Retrospective Study in Korean Girls

Gonadotropin-releasing hormone agonist (GnRHa) therapy is used to control puberty progression and it preserves height potential in patients with idiopathic central precocious puberty (ICPP). This study evaluated the correlation between weight and height gain at menarche following GnRHa treatment among girls with ICPP and relatively central early puberty (EP). We investigated height/weight trends and changes in height from diagnosis to menarche in girls with ICPP and EP treated with GnRHa. The mean difference in height (Delta height) from treatment cessation to menarche was 9.79 +/- 3.53 cm. Girls were divided into girls with Delta height >= 9.79 cm (Group 1) and girls with Delta height < 9.79 cm (Group 2). Although near adult height was significantly higher in Group 1, the mean body mass index (BMI) and weight were significantly lower at diagnosis, treatment discontinuation, and menarche. The BMI and weight at the three time points were negatively correlated with height. Girls with higher BMI at all three time points had slower growth rates during the study period. Considering that BMI and body weight were closely related to Delta height, proper management of BMI and body weight of girls receiving early puberty treatment might contribute to growth during and after GnRHa treatment.

Automated summary

This study evaluated the correlation between weight and height gain at menarche following GnRHa treatment among girls with idiopathic central precocious puberty (ICPP) and relatively central early puberty (EP). The results showed a negative correlation between high BMI and weight with slower height growth rates. Therefore, proper management of BMI and body weight is crucial for promoting height growth during and after early puberty treatment.